ERAP1 allotypes shape the epitope repertoire of virus-specific CD8
ERAP1
Epitope repertoire
HLA-B*27
Hepatitis C virus
T cells
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
25
06
2018
revised:
30
01
2019
accepted:
31
01
2019
pubmed:
16
2
2019
medline:
2
12
2020
entrez:
16
2
2019
Statut:
ppublish
Résumé
Endoplasmic reticulum aminopeptidase 1 (ERAP1) polymorphisms are linked with human leukocyte antigen (HLA) class I-associated autoinflammatory disorders, including ankylosing spondylitis and Behçet's disease. Disease-associated ERAP1 allotypes exhibit distinct functional properties, but it remains unclear how differential peptide trimming in vivo affects the repertoire of epitopes presented to CD8 We performed genetic and functional analyses of ERAP1 allotypes and characterized the HCV-specific CD8 Two hypoactive allotypic variants of ERAP1 were identified in an individual with acute HCV infection. The associated repertoire of virus-derived epitopes recognized by CD8 ERAP1 allotypes modify the virus-specific CD8 Endoplasmic reticulum aminopeptidase 1 (ERAP1) plays a key role in antigen presentation. Genetic variants of ERAP1 (leading to distinct allotypes) are linked with specific autoinflammatory disorders, such as ankylosing spondylitis and Behçet's disease. We found that ERAP1 allotypes modified the repertoire of virus-specific CD8
Sections du résumé
BACKGROUND & AIMS
Endoplasmic reticulum aminopeptidase 1 (ERAP1) polymorphisms are linked with human leukocyte antigen (HLA) class I-associated autoinflammatory disorders, including ankylosing spondylitis and Behçet's disease. Disease-associated ERAP1 allotypes exhibit distinct functional properties, but it remains unclear how differential peptide trimming in vivo affects the repertoire of epitopes presented to CD8
METHODS
We performed genetic and functional analyses of ERAP1 allotypes and characterized the HCV-specific CD8
RESULTS
Two hypoactive allotypic variants of ERAP1 were identified in an individual with acute HCV infection. The associated repertoire of virus-derived epitopes recognized by CD8
CONCLUSIONS
ERAP1 allotypes modify the virus-specific CD8
LAY SUMMARY
Endoplasmic reticulum aminopeptidase 1 (ERAP1) plays a key role in antigen presentation. Genetic variants of ERAP1 (leading to distinct allotypes) are linked with specific autoinflammatory disorders, such as ankylosing spondylitis and Behçet's disease. We found that ERAP1 allotypes modified the repertoire of virus-specific CD8
Identifiants
pubmed: 30769005
pii: S0168-8278(19)30111-4
doi: 10.1016/j.jhep.2019.01.034
pmc: PMC6527866
pii:
doi:
Substances chimiques
Epitopes, T-Lymphocyte
0
Minor Histocompatibility Antigens
0
Aminopeptidases
EC 3.4.11.-
ERAP1 protein, human
EC 3.4.11.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1072-1081Subventions
Organisme : Wellcome Trust
ID : 100326/Z/12/Z
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom
Informations de copyright
Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Références
J Exp Med. 2001 Nov 19;194(10):1395-406
pubmed: 11714747
J Clin Invest. 2002 Aug;110(4):515-26
pubmed: 12189246
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15661-8
pubmed: 12441397
Gastroenterology. 2003 Jul;125(1):80-8
pubmed: 12851873
Hepatology. 2004 Jul;40(1):108-14
pubmed: 15239092
Gastroenterology. 2004 Sep;127(3):924-36
pubmed: 15362047
J Exp Med. 2004 Dec 20;200(12):1593-604
pubmed: 15611288
J Exp Med. 2005 Nov 21;202(10):1349-61
pubmed: 16287711
Hepatology. 2006 Mar;43(3):563-72
pubmed: 16496339
Immunity. 2006 Oct;25(4):533-43
pubmed: 17046682
J Virol. 2007 Jan;81(2):945-53
pubmed: 17079288
J Gen Virol. 2007 Jul;88(Pt 7):1986-91
pubmed: 17554032
Nat Genet. 2007 Nov;39(11):1329-37
pubmed: 17952073
J Virol. 2008 Apr;82(7):3438-51
pubmed: 18216107
Hepatology. 2008 Jun;47(6):1824-36
pubmed: 18454507
J Clin Invest. 2009 Feb;119(2):376-86
pubmed: 19139562
Nature. 2009 Oct 8;461(7265):798-801
pubmed: 19759533
Hum Mol Genet. 2010 Dec 1;19(23):4705-14
pubmed: 20843824
Nat Genet. 2011 Jul 10;43(8):761-7
pubmed: 21743469
Hepatology. 2011 Oct;54(4):1157-66
pubmed: 22006856
Mol Cell Proteomics. 2012 Nov;11(11):1416-29
pubmed: 22918227
Nat Genet. 2013 Feb;45(2):202-7
pubmed: 23291587
AIDS. 2013 Jul 17;27(11):1697-706
pubmed: 23435305
J Immunol. 2013 Jul 1;191(1):35-43
pubmed: 23733883
Mol Immunol. 2014 Jan;57(1):12-21
pubmed: 23916068
Autoimmunity. 2013 Dec;46(8):497-508
pubmed: 24028501
Arthritis Rheumatol. 2014 Feb;66(2):284-94
pubmed: 24504800
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17594-9
pubmed: 25422414
Immunol Res. 2014 Dec;60(2-3):257-69
pubmed: 25434650
Arthritis Rheumatol. 2015 Mar;67(3):692-701
pubmed: 25469497
J Innate Immun. 2015;7(3):275-89
pubmed: 25591727
Lancet. 2015 Mar 21;385(9973):1124-35
pubmed: 25687730
Curr Opin Rheumatol. 2015 Jul;27(4):349-56
pubmed: 26002026
Dig Dis. 2016;34(4):396-409
pubmed: 27170395
Nat Rev Immunol. 2016 Aug;16(8):509-23
pubmed: 27374637
Mol Immunol. 2016 Sep;77:193-204
pubmed: 27522479
J Biol Chem. 2017 Jun 9;292(23):9680-9689
pubmed: 28446606
Clin Exp Immunol. 2017 Dec;190(3):281-290
pubmed: 28759104
Hum Immunol. 2017 Nov;78(11-12):731-738
pubmed: 29037997
J Clin Invest. 1995 Nov;96(5):2311-21
pubmed: 7593618